Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Feb 18;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. [Epub ahead of print]

PMID:
29466768
2.

Obesity and gynaecological and obstetric conditions: umbrella review of the literature.

Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Mitra A, Terzidou V, Bennett P, Martin-Hirsch P, Tsilidis KK, Kyrgiou M.

BMJ. 2017 Oct 26;359:j4511. doi: 10.1136/bmj.j4511. Review.

3.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.

Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D.

Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.

PMID:
28972047
4.

Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.

Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM.

J Surg Oncol. 2017 Aug 8. doi: 10.1002/jso.24801. [Epub ahead of print]

PMID:
28787528
5.

The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.

Zanini E, Louis LS, Antony J, Karali E, Okon IS, McKie AB, Vaughan S, El-Bahrawy M, Stebbing J, Recchi C, Gabra H.

Mol Cancer Ther. 2017 Oct;16(10):2246-2256. doi: 10.1158/1535-7163.MCT-17-0081. Epub 2017 Aug 3.

PMID:
28775148
6.

WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.

Janczar S, Nautiyal J, Xiao Y, Curry E, Sun M, Zanini E, Paige AJ, Gabra H.

Cell Death Dis. 2017 Jul 27;8(7):e2955. doi: 10.1038/cddis.2017.346.

7.

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.

PMID:
28525846
8.

British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.

Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, Kehoe S, Ledermann J, Morrison J, Naik R, Rolland P, Sundar S.

Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:123-139. doi: 10.1016/j.ejogrb.2017.04.016. Epub 2017 Apr 18. No abstract available.

PMID:
28457647
9.

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA.

Br J Cancer. 2017 May 9;116(10):1294-1301. doi: 10.1038/bjc.2017.86. Epub 2017 Mar 30.

10.

Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.

Phelps DL, Borley JV, Flower KJ, Dina R, Darb-Esfahani S, Braicu I, Sehouli J, Fotopoulou C, Wilhelm-Benartzi CS, Gabra H, Yazbek J, Chatterjee J, Ip J, Khan H, Likos-Corbett MT, Brown R, Ghaem-Maghami S.

Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.

11.

Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case Series.

Domenici L, Nixon K, Sorbi F, Kyrgiou M, Yazbek J, Hall M, Campbell J, Gibbons N, Park WE, Gabra H, Fotopoulou C.

Int J Gynecol Cancer. 2017 May;27(4):759-767. doi: 10.1097/IGC.0000000000000936.

PMID:
28338493
12.

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.

Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM.

Invest New Drugs. 2017 Oct;35(5):627-633. doi: 10.1007/s10637-017-0444-1. Epub 2017 Mar 10.

PMID:
28283779
13.

Adiposity and cancer at major anatomical sites: umbrella review of the literature.

Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Martin-Hirsch P, Tsilidis KK.

BMJ. 2017 Feb 28;356:j477. doi: 10.1136/bmj.j477. Review.

14.

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, Chiva L, Gabra H, Colombo N, du Bois A.

J Clin Oncol. 2017 Feb 20;35(6):587-590. doi: 10.1200/JCO.2016.71.0723. Epub 2017 Jan 9. No abstract available.

PMID:
28068169
15.

TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.

Amoroso MR, Matassa DS, Agliarulo I, Avolio R, Lu H, Sisinni L, Lettini G, Gabra H, Landriscina M, Esposito F.

Cell Death Dis. 2016 Dec 15;7(12):e2522. doi: 10.1038/cddis.2016.400.

16.

Endocrine therapy in epithelial ovarian cancer.

Langdon SP, Gourley C, Gabra H, Stanley B.

Expert Rev Anticancer Ther. 2017 Feb;17(2):109-117. doi: 10.1080/14737140.2017.1272414. Epub 2016 Dec 24. Review.

PMID:
27967255
17.

Gastrointestinal complications associated with the surgical treatment of heart disease in children.

Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO.

J Pediatr Surg. 2017 Mar;52(3):414-419. doi: 10.1016/j.jpedsurg.2016.10.052. Epub 2016 Nov 14.

PMID:
27916446
18.

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.

Alifrangis C, Thornton A, Fotopoulou C, Krell J, Gabra H.

Gynecol Oncol Rep. 2016 Nov 6;18:42-44. eCollection 2016 Nov.

19.

Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.

Nasser S, Lazaridis A, Evangelou M, Jones B, Nixon K, Kyrgiou M, Gabra H, Rockall A, Fotopoulou C.

Gynecol Oncol. 2016 Nov;143(2):264-269. doi: 10.1016/j.ygyno.2016.08.322. Epub 2016 Aug 29.

PMID:
27586894
20.

The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.

Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, Gabra H, Thiery JP, Huang RY.

Sci Signal. 2016 Oct 4;9(448):ra97.

PMID:
27703030
21.

Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.

Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Castillo-Tong DC, Wisman GBA, Berns EM, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2017 May 1;23(9):2213-2222. doi: 10.1158/1078-0432.CCR-16-1754. Epub 2016 Sep 23.

PMID:
27663594
22.

Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.

Wu W, Wang Q, Yin F, Yang Z, Zhang W, Gabra H, Li L.

Int J Oncol. 2016 Oct;49(4):1651-65. doi: 10.3892/ijo.2016.3652. Epub 2016 Aug 10.

PMID:
27511453
23.

Integrative Analysis of Subcellular Quantitative Proteomics Studies Reveals Functional Cytoskeleton Membrane-Lipid Raft Interactions in Cancer.

Shah AD, Inder KL, Shah AK, Cristino AS, McKie AB, Gabra H, Davis MJ, Hill MM.

J Proteome Res. 2016 Oct 7;15(10):3451-3462. Epub 2016 Sep 2.

PMID:
27384440
24.

Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.

Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I, Zanini E, Mazzoccoli C, Recchi C, Stronach E, Marone G, Gabra H, Matarese G, Landriscina M, Esposito F.

Cell Death Differ. 2016 Sep 1;23(9):1542-54. doi: 10.1038/cdd.2016.39. Epub 2016 May 20.

25.

Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.

Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, Farthing A, Brett S, Roux R, Hall M, Rustin G, Gabra H, Jiao L, Stümpfle R.

Arch Gynecol Obstet. 2016 Sep;294(3):607-14. doi: 10.1007/s00404-016-4080-3. Epub 2016 Apr 4.

PMID:
27040418
26.

Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.

Kyriakides M, Rama N, Sidhu J, Gabra H, Keun HC, El-Bahrawy M.

Oncotarget. 2016 Feb 9;7(6):7216-26. doi: 10.18632/oncotarget.6891.

27.

Introduction to managing patients with recurrent ovarian cancer.

Gabra H.

EJC Suppl. 2014 Dec;12(2):2-6. doi: 10.1016/S1359-6349(15)70003-0. Epub 2015 Jan 13.

28.

Foreword.

Gabra H.

EJC Suppl. 2014 Dec;12(2):1. doi: 10.1016/S1359-6349(15)70002-9. Epub 2015 Jan 13. No abstract available.

29.

A method for voltage measurements of cancerous vs non-cancerous omentum.

Wu W, Vitharana K, Gorgy T, Paterson A, Cunnea P, Gabra H, Fotopoulou C, Boutelle MG, Drakakis EM.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7514-7. doi: 10.1109/EMBC.2015.7320130.

PMID:
26738030
30.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. No abstract available.

PMID:
26503049
31.

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.

Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA.

Oncotarget. 2015 Dec 8;6(39):41736-49. doi: 10.18632/oncotarget.6153.

32.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

33.

Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.

Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, Rama N, Chen M, Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison S, Krachey E, Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H.

J Nucl Med. 2015 Dec;56(12):1828-35. doi: 10.2967/jnumed.115.156505. Epub 2015 Oct 1.

34.

The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.

Stronach EA, Cunnea P, Turner C, Guney T, Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB, Sriraksa R, Gabra H, El-Bahrawy M.

Oncotarget. 2015 Oct 13;6(31):31593-603. doi: 10.18632/oncotarget.3415.

35.

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AK.

Eur J Cancer. 2015 Sep;51(14):1978-88. doi: 10.1016/j.ejca.2015.07.012. Epub 2015 Jul 31.

PMID:
26238017
36.

The next steps in improving the outcomes of advanced ovarian cancer.

Openshaw MR, Fotopoulou C, Blagden S, Gabra H.

Womens Health (Lond). 2015 Jun;11(3):355-67. doi: 10.2217/whe.15.6. Review.

PMID:
26102473
37.

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410. Erratum in: Nature. 2015 Nov 19;527(7578):398.

PMID:
26017449
38.

Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.

Rizzuto I, Stavraka C, Chatterjee J, Borley J, Hopkins TG, Gabra H, Ghaem-Maghami S, Huson L, Blagden SP.

Int J Gynecol Cancer. 2015 Mar;25(3):416-22. doi: 10.1097/IGC.0000000000000361.

39.

LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression.

Mura M, Hopkins TG, Michael T, Abd-Latip N, Weir J, Aboagye E, Mauri F, Jameson C, Sturge J, Gabra H, Bushell M, Willis AE, Curry E, Blagden SP.

Oncogene. 2015 Sep 24;34(39):5025-36. doi: 10.1038/onc.2014.428. Epub 2014 Dec 22.

40.

The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.

Al Bakir M, Gabra H.

Br Med Bull. 2014 Dec;112(1):57-69. doi: 10.1093/bmb/ldu034. Review.

PMID:
25473022
41.

Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation.

Hopkins TG, Stavraka C, Gabra H, Fallowfield L, Hood C, Blagden S.

Climacteric. 2015 Feb;18(1):94-8. doi: 10.3109/13697137.2014.929104. Epub 2014 Jul 16.

PMID:
25029389
42.

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.

Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, Pledge S, Paul J, Mackean M, Hall GD, Gabra H, Halford SE, Walker J, Appleton K, Ullah R, Kaye S; Scottish Gynaecological Trials Group.

Br J Cancer. 2014 Apr 15;110(8):1923-9. doi: 10.1038/bjc.2014.116. Epub 2014 Mar 18.

43.

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.

Fotopoulou C, Vergote I, Mainwaring P, Bidzinski M, Vermorken JB, Ghamande SA, Harnett P, Del Prete SA, Green JA, Spaczynski M, Blagden S, Gore M, Ledermann J, Kaye S, Gabra H.

Ann Oncol. 2014 Jan;25(1):160-5. doi: 10.1093/annonc/mdt515. Epub 2013 Dec 5.

PMID:
24318743
44.

Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.

Curry EW, Stronach EA, Rama NR, Wang YY, Gabra H, El-Bahrawy MA.

Mod Pathol. 2014 Mar;27(3):433-42. doi: 10.1038/modpathol.2013.130. Epub 2013 Aug 16.

45.

Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.

O'Cathail SM, Shaboodien R, Mahmoud S, Carty K, O'Sullivan P, Blagden S, Gabra H, Whear S, Kwon JS, Agarwal R.

Int J Gynecol Cancer. 2013 Sep;23(7):1318-25. doi: 10.1097/IGC.0b013e31829f1799.

PMID:
23907557
46.

Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.

Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, Curry E, Gabra H, Stronach E, El-Bahrawy M.

Cytokine. 2013 Oct;64(1):413-21. doi: 10.1016/j.cyto.2013.05.006. Epub 2013 May 30.

PMID:
23727325
47.

Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential.

Frede J, Fraser SP, Oskay-Özcelik G, Hong Y, Ioana Braicu E, Sehouli J, Gabra H, Djamgoz MB.

Eur J Cancer. 2013 Jul;49(10):2331-44. doi: 10.1016/j.ejca.2013.03.016. Epub 2013 May 16. Review.

PMID:
23683551
48.

Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.

Shaboodien R, Diamantis N, Blagden S, Gabra H, Agarwal R.

Int J Gynecol Cancer. 2013 Mar;23(3):481-7. doi: 10.1097/IGC.0b013e31828702f6.

PMID:
23392404
49.

A study to evaluate the cause of bone demineralization in gynecological cancer survivors.

Stavraka C, Maclaran K, Gabra H, Agarwal R, Ghaem-Maghami S, Taylor A, Dhillo WS, Panay N, Blagden SP.

Oncologist. 2013;18(4):423-9. doi: 10.1634/theoncologist.2012-0416. Epub 2013 Jan 30.

50.

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Chee JL, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, Phua YT, Gabra H, Lim TM.

Cell Cycle. 2013 Jan 15;12(2):278-88. doi: 10.4161/cc.23054. Epub 2012 Jan 15.

Supplemental Content

Support Center